RecruitingPhase 1NCT06723236
A Study of MGC028 in Participants With Advanced Solid Tumors
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- MacroGenics
- Principal Investigator
- Pepi Pencheva, M.D.MacroGenics
- Intervention
- MGC028(biological)
- Enrollment
- 124 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (6)
- UCSF - Helen Diller Family Cancer Center, San Francisco, California, United States
- Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
- Icahn School of Medicine at Mt. Sinai, New York, New York, United States
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio, Texas, United States
- South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06723236 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University